市場調查報告書
商品編碼
938843

C反應性蛋白質(CRP)檢驗市場

C-reactive Protein Testing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球C反應性蛋白質(CRP)檢驗市場在預測期間內預計將以1.4%的年複合成長率增長,達到1億6,440萬美元的規模。

本報告提供全球C反應性蛋白質(CRP)檢驗市場的相關調查,提供市場佔有率,趨勢和成長要素,新型冠狀病毒感染疾病的影響,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

本報告刊載的企業資料:Abaxis, Inc.·Abbott Laboratories·Danaher Corporation·F. Hoffmann-La Roche AG·Laboratory Corporation of America Holdings (LabCorp)·Merck KgaA·Quest Diagnostics, Inc.·Randox Laboratories Ltd.·Siemens Healthineers·Thermo Fisher Scientific, Inc.

目錄

簡介,調查手法,調查範圍

摘要整理

第1章 市場概要

  • 全球競爭市場佔有率
  • 全球競爭市場佔有率方案
  • 新型冠狀病毒感染疾病的影響,全球景氣衰退

第2章 焦點企業

第3章 市場趨勢及成長要素

第4章 全球市場預測

市場分析

  • 各地區市場分析
  • 美國
    • 市場現狀·要點
    • 市場佔有率:各企業
    • 市場分析
  • 加拿大
  • 歐洲
    • 市場現狀·要點
    • 競爭的市場佔有率方案
    • 市場分析
  • 南美
  • 亞太地區
  • 中東
  • 非洲

競爭

  • 企業簡介
目錄
Product Code: MCP11362

Abstract:

Global C-reactive Protein Testing Market to Reach $1.8 Billion by 2027

Amid the COVID-19 crisis, the global market for C-reactive Protein Testing estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 1.4% over the analysis period 2020-2027. Cardiovascular Diseases, one of the segments analyzed in the report, is projected to record a 1.8% CAGR and reach US$531.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cancer segment is readjusted to a revised 1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $466 Million, While China is Forecast to Grow at 1.1% CAGR

The C-reactive Protein Testing market in the U.S. is estimated at US$466 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$308.6 Million by the year 2027 trailing a CAGR of 1.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.4% and 0.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Rheumatoid Arthritis Segment to Record 1.7% CAGR

In the global Rheumatoid Arthritis segment, USA, Canada, Japan, China and Europe will drive the 1.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$170.1 Million in the year 2020 will reach a projected size of US$191.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$196.1 Million by the year 2027.

Select Competitors (Total 43 Featured) -

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings (LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • What is C-reactive Protein (CRP)?
    • An Introduction to C-reactive Protein Testing
    • Global Market Prospects & Outlook
    • Immunoturbidimetric Assays: The Major Segment by Assay Type
    • hs-CRP Test Type Leads by Detection Range
    • Cardiovascular Diseases Emerge As the Leading Disease Type for CRP Testing, Cancer Detection to Make Strong Gains
    • Clinics & Hospitals Hold Dominant Share of CRP Testing Market
    • Developed Regions Lead, Developing Economies to Spur Market Growth
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prominence of POC Testing Approaches for C-reactive Protein Testing Enable Faster and Accurate Results
    • Growing Approval for CRP Testing for Identification of Bacterial and Non-Bacterial Diseases to Propel Market Growth
    • CRP Testing for Ascertaining Viral Infections
    • Growing Incidence of HIV Infections and Need for Monitoring of HIV Diseases Drive CRP Testing
    • Rising Importance of CRP Testing for Cardiovascular Diseases
    • EXHIBIT 1: Cardiovascular Disease Incidence Rates (per 100,000) by Select Countries
    • Rising Prevalence of Inflammatory Diseases: Opportunity for CRP Testing
    • Threat of Endometriosis in Women: Significant Role of CRP Testing
    • CRP Testing: A Vital Diagnostic Tool for Cancer
    • Advancements in CRP Testing Methods
    • CRP Testing Holds Potential Role in Assessing Effectiveness of Antibiotic Drugs
    • Funding Support for Extensive Research on Applications of C-reactive Protein Testing to Boost Market Growth
    • CRP Testing Brings to Light Issues Related to Data Integrity & Testing Reliability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for C-reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for C-reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for C-reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Lupus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Home by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Home by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Home by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 43: USA Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 46: USA Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 49: Canada Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Canada Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Canada 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 52: Canada Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Canada Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Canada 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 55: Japan Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 58: Japan Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Japan Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Japan 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 61: China Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 64: China Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 67: Europe Current & Future Analysis for C-reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for C-reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for C-reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 76: France Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: France Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: France 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 79: France Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 82: Germany Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Germany Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Germany 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 85: Germany Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Germany Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Germany 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 88: Italy Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Italy Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Italy 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 91: Italy Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Italy Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Italy 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 94: UK Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: UK Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: UK 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 97: UK Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: UK Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: UK 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Rest of Europe Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Rest of Europe 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 103: Rest of Europe Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of Europe Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of Europe 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 106: Asia-Pacific Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Asia-Pacific Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Asia-Pacific 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 109: Asia-Pacific Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Asia-Pacific 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 112: Rest of World Current & Future Analysis for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of World Historic Review for C-reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of World 15-Year Perspective for C-reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2012, 2020 & 2027
    • TABLE 115: Rest of World Current & Future Analysis for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of World Historic Review for C-reactive Protein Testing by End-Use - Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of World 15-Year Perspective for C-reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43